Sanghee Hong

A study of 567 people who were alive and cancer-free 1 year after #BMT found that most were highly confident about knowledge in their survivorship. Learn more about this CIBMTR study: cibmtr.org/Files/Patient-…

We are happy to share Prof. Fleischhauer's commentary on this very relevant study by our @CIBMTR colleagues, now available in @ASTCT_Journal. Incorporating #HLA-DP permissive mismatches results in optimal likelihoods of finding well-matched unrelated donors for our #HCT patients!

@ASTCT Excited to join this conversation: we learned to focus more on Health burden (i.e., fatigue) of older survivors and also to provide community resources.

#ASTCTChat Q1: How do the findings of this paper impact your survivorship plan? ow.ly/8Pce50Nlzxa

Yes, clonal evolution in MF does matter! 🙏 To @NicoGagelmann for leading this amazing collaboration !

Join the Education Committee this Thursday, March 23, for the next #ASTCTChat. Starting at 9 AM CT, questions will be posted hourly on Twitter. Join in the conversation using #ASTCTChat: ow.ly/8Pce50Nlzxa

#Tandem23 Twitter is dated. The future belongs to TikTok. ⁦@BeTheMatch⁩ needs to immediately engage with Dr Fingrut.

@pagliuca_simona Congratulations!

So proud of our gigantic effort to districate the complexity of clonal evolution in AA and PNH: a comprehensive integration of clinical and genomic data to give answer to many unsolved issues. This is a huge team effort led by many great minds and mentors.

Brilliant overview of the hla loss mechanism and frequency across donors, cord blood cells have unique properties, by @vago_luca at @TheEBMT #ITC22, @TheEBMT_Trainee

Today the @WhiteHouse announced that all federally funded research will be made openly available. Importantly, it eliminates the 12-month embargo. This is the result of decades of work by @SPARC_NA, @petersuber, @mbeisen, and so many more. #OpenAccess whitehouse.gov/ostp/news-upda…

@AaronGoodman33 @BldCancerDoc @NEJM @BMTjournal Truly polypharmacy is a huge issue, and I can’t agree more on the need of more data from rct!

The Phase 3 study of Gilt + Aza vs Aza in newly-dx FLT3m AML in pts that could not receive intensive chemo is out in @BloodJournal ! #leusm -mOS 9.82 mon Gilt + Aza and 8.87 mon Aza (p=.75) -similar CR rates: Gilt + aza 16.2%, Aza 14.3% ashpublications.org/blood/article/…

@khera_nandita @DukeHMCT @dukemedicine @DukeCancer Thank you @khera_nandita. Looking forward to working with you more in health services space and beyond!

@DukeHMCT @hongsmd @dukemedicine @DukeCancer Congrats Sanghee!! Wishing you all the best for the new job!!

A warm welcome to @hongsmd, our newest faculty @DukeHMCT @dukemedicine @DukeCancer. Dr. Hong joins us as Asst Prof with a clinical focus in #leukemia & #BMT & research focus in health disparities & social issues in BMT & prevention/mgmt of relapse post-BMT.

@DukeHMCT @dukemedicine @DukeCancer @DukeHMCT @dukemedicine @dukecancer Very excited to join this amazing group and looking forward to working with everyone.

#ASH21 anti-leukemic effect by inducing p21 by MDM2/XPO1 inhibition for van/HMA resistant AML by Yuki Nishida from MD Anderson @VisconteValeria

@BldCancerDoc @JuliaJoo4 @CleClinicMD You are an exceptional mentor! I am so happy to be your mentee.

@hongsmd discussing her upcoming presentations here at #ASH19 #CleClinicCancer @CleClinicMD

📢Study evaluating the role of vitamin D and its association with hematopoietic cell transplantation outcomes, including #GvHD incidence. 👏@hongsmd @hamiltkyb @chrisfarraroCNP. #gvhdsm #bmtsm

Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of nonrelapse mortality after allogeneic hematopoietic cell transplantation. ow.ly/NlWf50BZK3c @BldCancerDoc @hongsmd @wlsaber @CIBMTR

Awesome oral presentation by @JuliaJoo4 on community health status and long terms transplant outcomes. #ASH21 @BldCancerDoc @hamiltkyb

#ASH21 @warren_fingrut Important work presented on donor and optimal donor availability based on race. Outstanding presentation, and looking forward to presentation #TCT